Targeted & controlled bone healing
  • slidebg1
  • slidebg1
  • slidebg1
Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

Kuros Biosciences are experts in the science of orthobiologics.

Our technology platforms aim to deliver improved patient outcomes through targeted and controlled bone healing.

We are poised to realise this aim through the launch of MagnetOs, based on our flagship surface science technology, and through the expansion of our portfolio by the continued clinical development of products based on our novel TG Hook technology.

Latest News
03 Sep 19
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograft Primary endpoint is radiographic interbody fusion at 12 months READ MORE

20 Aug 19
Kuros Biosciences Reports Results for First Half 2019
Financial highlights CHF 13.4 million cash and cash equivalents (including trade and other receivables) at June 30, 2019 Product sales were CHF 0.9 million in the first half of 2019, a substantial increase compared to H1 2018   Operational highlights year-to-date Partner SeaSpine has initiated commercial rollout of bone graft supplied by Kuros and marketed under the brands OsteoCurrent and Current Increased commercial footprint with distribution agreement with Surgical Specialties in Australia and New Zealand Preparation for Phase II clinical study of Fibrin-PTH in spinal fusion on track READ MORE

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

Kuros Biosciences are experts in the science of orthobiologics.

Our technology platforms aim to deliver improved patient outcomes through targeted and controlled bone healing.

We are poised to realise this aim through the launch of MagnetOs, based on our flagship surface science technology, and through the expansion of our portfolio by the continued clinical development of products based on our novel TG Hook technology.

Latest News
03 Sep 19
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograft Primary endpoint is radiographic interbody fusion at 12 months READ MORE

20 Aug 19
Kuros Biosciences Reports Results for First Half 2019
Financial highlights CHF 13.4 million cash and cash equivalents (including trade and other receivables) at June 30, 2019 Product sales were CHF 0.9 million in the first half of 2019, a substantial increase compared to H1 2018   Operational highlights year-to-date Partner SeaSpine has initiated commercial rollout of bone graft supplied by Kuros and marketed under the brands OsteoCurrent and Current Increased commercial footprint with distribution agreement with Surgical Specialties in Australia and New Zealand Preparation for Phase II clinical study of Fibrin-PTH in spinal fusion on track READ MORE